
|Articles|July 8, 2008
New therapy enters trials
INO-8875, an Adenosine 1 agonist in Phase I testing for the treatment of glaucoma, has begun patient enrolment.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
How Digital Workflow Boosted my Confidence and Elevated Premium Patient Rates in Cataract Surgery
2
From skepticism to clarity and focus: A family’s PRESBYOND experience
3
Evolving Practice In Retinal Care A Question Of Control
4
Real-World Burden of Demodex Blepharitis in the UK
5















































